- Prognostic significance of long non-coding RNA five prime to XIST in various cancers. - Background: To observe the clinicopathological and prognostic value of long non-coding RNA five prime to X inac- tive specific transcript (lncFTX) in multiple tumors.. - We used The Cancer Genome Atlas (TCGA) dataset to further investigate the differential expression and prognostic value of lncFTX.. - The results showed that the expression of lncFTX was positively associated with advanced TNM stage (III-IV versus I-II) (OR CI P <. - However, the expression of lncFTX was not associated with tumor differentiation (poor differentiation versus well or moderate differentiation) and vessel invasion of cancer.. - Subgroup analysis showed that the higher lncFTX expression was associated with shorter overall survival in cancer patients, regardless of the sample size and cancer type. - No publication bias was found, and the sensitivity analysis results suggested that the main findings were robust. - Conclusions: This study found that the expression of lncFTX was positively associated with advanced tumor node metastasis (TNM) stage, lymph nodes, distant metastasis and, cancer mortality, suggesting that lncFTX might be a potential prognostic biomarker for tumors.. - The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. - If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. - In the United States, 606,880 cancer related deaths and 1,762,450 new can- cer cases were projected to occur in 2019 [1]. - One of the main reasons that lead to the poor prognosis in cancer patients is that the failure to detect the cancer at early stage. - Long non-coding RNA five prime to X inactive spe- cific transcript (LncRNA) refers to a type of non-coding RNA with a molecular length of more than 200 nucleo- tides. - Some long-chain non-coding RNAs were found that increased significantly in tumor tissues. - It produces a long non-coding RNA splicing sequence, which can significantly up-regulate the expression of XIST. - In this regard, we conducted this systematic review and meta-analysis to comprehensively examine the relationship between the expression of lncFTX and the prognosis of cancer patients.. - PubMed: lncRNA or long non-coding RNA, FTX or five prime to XIST, survival, and cancers;. - Embase: lncRNA or long non-coding RNA, FTX or five prime to XIST, prognosis, cancers;. - Web of Science: lncRNA or long non-coding RNA, FTX or five prime to XIST, clinical outcome or survival, cancers or tumor or carcinoma or sarcoma;. - Cochrane Library databases: lncRNA or long non-cod- ing RNA, FTX or five prime to XIST, prognosis or sur- vival, cancers or tumor or carcinoma or sarcoma.. - (1) Studies with the aim of assessing clinical-patholog- ical or prognostic significance of lncFTX in human cancers.. - (3) Studies provided relevant data that can be used for this meta-analysis.. - (2) The value of the cut-off point of a high expression of lncFTX was not provided.. - Two investigators (JZ, WW) extracted the information of eligible studies including the name of first author, year of publication, study design, country, type of sam- ple, cancer type, study sample size, number of patients with high/low (H/L) expression of lncFTX, gender, inclusion period, follow-up time and method.. - In the present study, NOS was used. - 6 stars were enrolled in the present study.. - Study results for the association between the expression of lncFTX and prognosis of multiple cancers were reported as odds ratio (OR)/hazard ratio (HR) value with 95% confidence interval (CI). - cn/) to compare the expression of FTX between sarcoma tissues and normal tissues.. - We obtained 59 articles in the initial search. - After remov- ing 16 papers due to duplication and 32 papers that did not meet the eligibility criteria though the full-text read- ing, we included 11 papers published between 2015 and 2020 in the final analysis (Fig. - Characteristics of included studies and quality evaluation A total of 11 studies with 1633 cancer patients were included in this meta-analysis. - Quantitative real-time polymerase chain reaction (qRT-PCR) was used to detect the expression of lncFTX in these included studies. - Association between the expression of lncFTX and cancer clinicopathological features. - 2, we found that an elevated expres- sion of lncFTX was significantly associated with more advanced TNM stage (III-IV VS I-II) (OR CI:. - OR/HR, 95% CI and the heterogeneity of this meta-analysis were pre- sented in Table 2.. - In sensitivity analysis by removing one study iteratively in the meta-analysis for each study outcome, the ORs with their corresponding CIs varied in the range from 1.03 (95% CI to 1.91 (95% CI for tumor differentiation (Fig. - 3A), from 2.10 (95% CI: 1.56–. - 3B), from 1.18 (95% CI to 1.32 (95% CI for vessel invasion (Fig. - 3C), from 2.54 (95% CI to 3.52 (95% CI for lymph nodes metastasis (Fig. - 3D), from 3.42 (95% CI:. - 1.85–6.33) to 3.98 (95% CI for distant metas- tasis (Fig. - 3E), and the HRs varied in the range from 1.58 (95% CI to 2.02 (95% CI for over- all survival (Fig. - In terms of potential publication bias, no asymmetry was observed in the funnel plot (Fig. - Association between elevated expression of lncFTX and survival for cancers. - Results from eight included studies (Table 3) were pooled to analyze the association between high expression of lncFTX and survival rates for multiple cancers. - We found that higher expression of lncFTX was asso- ciated with a greater cancer mortality in studies with sample size less than 100 (HR CI . - Additionally, the results of subgroup analysis showed that elevated expression of lncFTX was associated with shortened OS of glioma (HR . - Sensitivity analysis showed that the consistent result and the HR was in the range from 1.58 (95% CI:. - 1.27–1.97) to 2.02 (95% CI for overall survival (Fig. - We found a significant difference in the FTX expression between normal tissues and multiple cancer types including cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), acute myeloid leukemia (LAML), ovarian serous cystadenocarcinoma Fig. - MethodSurvival analysisNOS score 1Liang et al.2020RetrospectiveChinaTissueGlioma qRT-PCRMultivariate8 2Zhao et al.2020RetrospectiveChinaTissueColorectal cancer qRT-PCR–7 3Zhang et al.2020RetrospectiveChinaTissueGastric cancer qRT-PCRUnivariate8 4Jiang et al.2019RetrospectiveChinaTissueGastric cancer qRT-PCR–7 5Vasquez et al.2019RetrospectiveAmericanTissueEndometrial carcinoma543–––60qRT-PCRUnivariate8 6Li et al.2018RetrospectiveChinaTissueOsteosarcoma qRT-PCRUnivariate8 7Yang et al.2018RetrospectiveChinaTissueColorectal cancer qRT-PCRUnivariate8 8He et al.2017RetrospectiveChinaTissueRenal cell carci- noma qRT-PCR–7 9Liu et al.2016RetrospectiveChinaTissueHepatocellular carcinoma qRT-PCRUnivariate7 10Liu et al.2016RetrospectiveChinaTissueHepatocellular carcinoma qRT-PCRMultivariate8 11Guo et al.2015RetrospectiveChinaTissueColorectal cancer qRT-PCRUnivariate8. - Moreover, we found that the expression of FTX was significantly related to the advanced stage of cancers (p <. - We found that FTX was significantly associated with OS (p <. - In the past few decades, the association between human genes and tumor occurrence has raised growing interests. - recent studies pointed out that the expression of lncRNA is closely related to the occurrence and development of a variety of tumors at cellular and molecular levels The imbalanced lncRNA profile is widely involved in the occurrence and development of tumors, includ- ing tumor cell invasion, proliferation, migration, apopto- sis, epithelial-mesenchymal transition (EMT) and tumor resistance. - Studies have shown that LncRNA is dysregu- lated in the blood, urine, tumor tissue or other tissues in certain cancer patients, thus it may be used as a potential biomarker for cancer diagnosis [7, 32]. - LncFTX was located in the X-inactivation center. - 2 Association between lncFTX and clinical features of tumors. - Table 2 Correlation between high expression of lncFTX and clinicopathologic features for tumor. - Clinicopathologic features Studies OR/HR and 95% CI Effects model Heterogeneity (p. - Table 3 Features of papers for the meta-analysis of 5-year survival in cancers. - Liang et al. - Zhang et al. - Vasquez et al. - Li et al. - Yang et al. - Liu et al. - Guo et al. - To provide robust evidence, we conducted this meta- analysis of 11 studies comprising 1633 patients with tumors to systematically evaluate the prognostic value of lncFTX in various cancers. - The results of the present study indicated that the elevated expression of lncFTX was significantly associated with a more advanced TNM stage (III-IV VS I-II) (OR CI P <. - 95% CI P <. - Furthermore, in the analysis Table 4 Subgroup analyses for the relationship between high expression of lncFTX and the survival of patients with cancer. - Subgroup Studies HR and 95% CI Effects model Heterogeneity (p. - (A) Differential expression of FTX between sarcoma tissue and normal tissue. - for the prognostic role of FTX in cancer including 4668 patients with high FTX expression and 4691 patients with low FTX expression, the results indicated that the higher expression of FTX was significantly associated with lower OS (p <. - 0.05), suggesting that the FTX can be used as a prognostic biomarker for cancers.. - There are several limitations in the present study.. - In conclusion, this meta-analysis was conducted to observe the association between high expression of lncFTX and prognosis of various cancers. - lncFTX: Long non-coding RNA five prime to X inactive specific transcript;. - 95% CI: 95% confidence interval. - Nedelcu T, Kubista B, Koller A, Sulzbacher I, Mosberger I, Arrich F, et al.. - Partridge AH, Rumble RB, Carey LA, Come SE, Davidson NE, Di Leo A, et al.. - Non-coding RNAs in breast Cancer: intracellular and intercel- lular communication. - Zhao K, Ye Z, Li Y, Li C, Yang X, Chen Q, et al. - Liu Z, Dou C, Yao B, Xu M, Ding L, Wang Y, et al. - Ftx non coding RNA- derived miR-545 promotes cell proliferation by targeting RIG-I in hepato- cellular carcinoma. - Guo XB, Hua Z, Li C, Peng LP, Wang JS, Wang B, et al. - Biological signifi- cance of long non-coding RNA FTX expression in human colorectal cancer. - Expression of HER-2 in surgical specimen and biopsy as a biomarker of metastasis in patients with osteosarcoma: a meta-analysis. - Tu C, Ren X, He J, Zhang C, Chen R, Wang W, et al. - The prognostic value of long noncoding RNA SNHG16 on clinical outcomes in human cancers: a systematic review and meta-analysis. - Long non-coding RNA FTX promotes gastric cancer progression by targeting miR-215. - The relationship between the overexpression of long non-coding RNA FTX and the clinicopathological characteristics of gastric cancer. - Genome-wide analysis and functional prediction of the estrogen-regu- lated transcriptional response in the mouse uterusdagger. - Long non-coding RNA Ftx promotes osteosarcoma progression via the epithelial to mesenchymal transition mechanism and is associated with poor prognosis in patients with osteosarcoma. - Yang Y, Zhang J, Chen X, Xu X, Cao G, Li H, et al. - He X, Sun F, Guo F, Wang K, Gao Y, Feng Y, et al. - Knockdown of long non- coding RNA FTX inhibits proliferation, migration, and invasion in renal cell carcinoma cells. - Liu F, Yuan JH, Huang JF, Yang F, Wang TT, Ma JZ, et al. - Silencing of long non-coding RNA MIAT sensitizes lung Cancer cells to Gefitinib by epigenetically regulating miR- 34a
Xem thử không khả dụng, vui lòng xem tại trang nguồn hoặc xem
Tóm tắt